Nimesh Patel: Understanding Plasmapheresis – A Clinical Overview
Nimesh Patel, National Board Of Examinations in Medical Sciences at CKS Hospitals, shared a post on LinkedIn:
“Understanding Plasmapheresis: A Clinical Overview
Plasmapheresis—also known as therapeutic plasma exchange (TPE)—is a critical procedure used to remove large molecules such as pathogenic autoantibodies, immune complexes, or toxins from a patient’s plasma.
When the removal of circulating substances is required to halt or reverse disease progression, TPE becomes an essential intervention.
Key Clinical Indications
- Neurology: Myasthenia gravis, Guillain-Barré syndrome, and Chronic inflammatory demyelinating polyneuropathy (CIDP).
- Hematology: Thrombotic thrombocytopenic purpura (TTP) and Hyperviscosity syndrome.
- Nephrology: Anti-GBM disease (Goodpasture syndrome) and ANCA-associated vasculitis.
- Immunology and Other: Transplant rejection (ABO-incompatible) and Catastrophic antiphospholipid syndrome.
Potential Complications
While generally well-tolerated, the extracorporeal circuit and plasma replacement process carry inherent risks.
- Hypocalcemia: Commonly caused by citrate toxicity used for anticoagulation, which can lead to tingling, muscle cramps, or cardiac arrhythmias.
- Hypotension: Often related to volume shifts or patient sensitivity to the procedure.
- Infection/Access-related: Risks such as bacteremia or thrombosis associated with central venous catheter placement.
- Coagulopathy: Increased bleeding risk resulting from the removal of clotting factors.
- Allergic Reactions: Sensitivity to replacement fluids (e.g., albumin or fresh frozen plasma), ranging from mild urticaria to anaphylaxis.
Educational Disclaimer:
This content is intended for educational purposes only. Clinical decisions should always be individualized based on patient condition, clinical judgment, and institutional protocols.”

Stay updated with Hemostasis Today.
-
May 25, 2026, 15:00Tahsim Anwar: Highlighting Transfusion Therapy as a Cornerstone in the Management of SCD Complications
-
May 25, 2026, 14:58Samwel Mikaye: Pathophysiology, Clinical Features and Management of CAD
-
May 25, 2026, 14:57Rupam Manna: Approach and Management of Deep Vein Thrombosis in Cancer
-
May 25, 2026, 14:56Andrea Fischer: Celebrating Hematology Advocacy Recognition and New Achievements This Spring
-
May 25, 2026, 14:45Monica Schaller: How Do Autophagy, Inflammation, and NETs Interact to Drive Autoimmune Thrombosis?
-
May 25, 2026, 14:04Sophia Delicou: We Aim to Bridge Laboratory Insights and Clinical Practice for Unstable Hemoglobin Variants
-
May 25, 2026, 13:49Chaitanya Harita: Presenting AML Research at the British Society for Haematology Annual Scientific Meeting 2026
-
May 25, 2026, 13:04Mohammad Ameen Ishqair: Blood Group Antigens as Emerging Biomarkers in Disease
-
May 25, 2026, 13:04Dhruvi Joshi: Reduced-Dose DOAC Therapy in Patients With Venous Thromboembolism